Loading quotes...
Forecast
The analysts' average price target is €13.01 (-2.55%). The median is €13.01 (-2.55%).
| Buy |
6 |
| Hold |
4 |
| Sell |
2 |
Discussions in the community
There is no discussion about this asset yet.
Start discussionNews Go to news feed
There is currently no news available for this company. We are working on adding more providers to change this.
Historical dividends Dividends
All dividend metrics All metricsFinancials
| (EUR) | September 2026 | YoY |
|---|---|---|
| Revenue | 796.95M | 5.64% |
| Gross profit | 415.48M | 10.02% |
| Net profit | 85.02M | 38.33% |
| EBITDA | 157.75M | 32.34% |
Fundamentals
| Metric | Value |
|---|---|
Market capitalization | €11.14B |
Number of shares | 833.54M |
52-week high/low | €14.21 - €10.30 |
Dividend yield | 0.54% |
Dividends TTM | €0.0722 |
Beta | 0.25 |
P/E ratio | 41.07 |
PEG ratio | -0.79 |
P/B ratio | 2.98 |
P/S ratio | 3.49 |
Company profile
Dr. Reddy's Laboratories Limited, together with its subsidiaries, operates as an integrated pharmaceutical company worldwide. It operates through Global Generics, Pharmaceutical Services and Active Ingredients (PSAI), Proprietary Products, and Others segments. The Global Generics segment manufactures and markets prescription and over-the-counter finished pharmaceutical products that are marketed under a brand name or as a generic finished dosages with therapeutic equivalence to branded formulations. This segment also engages in the biologics business. The PSAI segment manufactures and markets active pharmaceutical ingredients and intermediates, which are principal ingredients for finished pharmaceutical products. This segment also provides contract research services; and manufactures and sells active pharmaceutical ingredients and steroids in accordance with the specific customer requirements. The Proprietary Products segment focuses on the research, development, and commercialization of differentiated formulations for dermatology and neurology therapeutic areas. The Others segment engages in developing therapies in the fields of oncology and inflammation. As of March 31, 2021, it had three late stage projects at various stages of development. Its therapeutic categories primarily include gastro-intestinal, cardiovascular, anti-diabetic, dermatology, oncology, respiratory, stomatology, urology, and nephrology. The company has a collaboration, license, and option agreement with Curis, Inc. to discover, develop, and commercialize small molecule antagonists for immuno-oncology and precision oncology targets. Dr. Reddy's Laboratories Limited was incorporated in 1984 and is headquartered in Hyderabad, India.
| Name | Dr Reddys Laboratories ADR |
| CEO | Erez Israeli |
| Headquarters | Hyderabad,
ts India |
| Website | |
| Sector | Health Care |
| Industry | Pharmaceuticals |
| IPO | 04/11/2001 |
| Employees | 27,527 |
Deep Dive
Ticker symbols
| Exchange | Symbol |
|---|---|
NYSE | RDY |
Frankfurt | RDDA.F |
Düsseldorf | RDDA.DU |
München | RDDA.MU |